We are live on ! Find out more
PARN

Parnell Pharmaceuticals Holdings Ltd
PARN

Delisted

PARN was delisted on the 30th of December, 2016.

Back to rankings

2 hedge funds and large institutions have $96K invested in Parnell Pharmaceuticals Holdings Ltd in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

33% less capital invested

Capital invested by funds: $143K → $96K (-$47K)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$96K

Top Sellers

1
SM
Sabby Management
Florida
-$143K
Name Holding Trade Value Shares
Change 		Change in
Stake
Alyeska Investment Group
1
Alyeska Investment Group
Illinois
$96K +$96K +147,458 New
SM
2
Sabby Management
Florida
– -$143K -170,000 Closed

PARN Hedge Fund Activity: Q3 2017 in Review

2 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Parnell Pharmaceuticals Holdings Ltd (PARN) for Q3 2017, worth a combined $96K — down 33% from $143K a quarter earlier.

Fund positioning in PARN was balanced in Q3 2017: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $96K. The largest seller was Sabby Management, exiting entirely with an estimated $143K sold.

  • 2 institutional investors held Parnell Pharmaceuticals Holdings Ltd (PARN) as of Q3 2017, unchanged from Q2 2017.
  • Funds reported $96K of Parnell Pharmaceuticals Holdings Ltd stock for Q3 2017, down 33% quarter-over-quarter.
  • 1 fund opened new Parnell Pharmaceuticals Holdings Ltd positions in Q3 2017 and 1 closed out, a net change of 0 holders.
  • The largest Parnell Pharmaceuticals Holdings Ltd buyer in Q3 2017 was Alyeska Investment Group, an estimated $96K added.
  • The largest Parnell Pharmaceuticals Holdings Ltd seller in Q3 2017 was Sabby Management, an estimated $143K sold.

Based on aggregated 13F filings for Q3 2017.